超进展性疾病是免疫治疗的一种特定现象吗？
Is hyperprogressive disease a specific phenomenom of immunotherapy?
作者信息
Brambilla Marta, Russo Giuseppe Lo, Ferrara Roberto, Manglaviti Sara, Garassino Marina Chiara, Occhipinti Mario
机构信息
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
Medical Oncology Unit B, Policlinico Umberto I "Sapienza" University of Rome, 00161 Rome, Italy.
出版信息
Explor Target Antitumor Ther. 2020;1(6):427-433. doi: 10.37349/etat.2020.00027. Epub 2020 Dec 28.
Abstract
Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.
摘要
超进展性疾病（HPD）是免疫治疗过程中一种新的反应模式。多项回顾性研究基于不同的定义标准评估了其在各种癌症类型中的发生率，尤其是在非小细胞肺癌患者中的发生率。HPD是否仅仅是免疫治疗的一种典型现象仍是一个未解决的问题。本文总结了其他癌症治疗中有关HPD的现有数据。
相似文献
1
Is hyperprogressive disease a specific phenomenom of immunotherapy?超进展性疾病是免疫治疗的一种特定现象吗？
Explor Target Antitumor Ther. 2020;1(6):427-433. doi: 10.37349/etat.2020.00027. Epub 2020 Dec 28.
2
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.程序性细胞死亡蛋白 1/程序性死亡配体 1 阻断时代下 Hyperprogressive 疾病的管理：病例讨论和文献复习。
Oncologist. 2020 May;25(5):369-374. doi: 10.1634/theoncologist.2019-0671. Epub 2020 Feb 24.
3
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.免疫治疗非小细胞肺癌中“超进展”定义的澄清。
JAMA Oncol. 2020 Jul 1;6(7):1039-1046. doi: 10.1001/jamaoncol.2020.1634.
4
[Advances in Hyperprogressive Disease in Patients
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].[接受免疫治疗的晚期非小细胞肺癌患者超进展性疾病的研究进展]
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):271-278. doi: 10.3779/j.issn.1009-3419.2021.101.08.
5
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.临床风险因素、CAR 指数以及免疫细胞组成变化对接受免疫治疗的非小细胞肺癌患者发生超进展性疾病的影响。
BMC Cancer. 2021 Jan 5;21(1):19. doi: 10.1186/s12885-020-07727-y.
6
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.免疫检查点阻断后发生的超进展性疾病：重点关注非小细胞肺癌。
Curr Oncol Rep. 2020 Apr 16;22(5):41. doi: 10.1007/s11912-020-00908-9.
7
Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.免疫治疗后 hyperprogressive 疾病的影像学标准比较。
Cancer Treat Rev. 2020 Dec;91:102116. doi: 10.1016/j.ctrv.2020.102116. Epub 2020 Oct 29.
8
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.免疫检查点抑制剂治疗下超进展性疾病中的免疫细胞。
Cells. 2022 May 27;11(11):1758. doi: 10.3390/cells11111758.
9
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
10
Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.接受免疫治疗的非小细胞肺癌患者的超进展性疾病。
J Thorac Dis. 2018 Feb;10(2):1124-1128. doi: 10.21037/jtd.2018.01.79.
引用本文的文献
1
Treatment of NSCLC after chemoimmunotherapy - are we making headway?化疗免疫治疗后非小细胞肺癌的治疗——我们有进展吗？
Nat Rev Clin Oncol. 2025 Aug 14. doi: 10.1038/s41571-025-01061-7.
2
Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.免疫检查点抑制剂治疗后转移性肾细胞癌患者出现的超进展性疾病：一例报告
Cureus. 2022 Oct 11;14(10):e30194. doi: 10.7759/cureus.30194. eCollection 2022 Oct.
本文引用的文献
1
Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient.更正：意外的发作：骨发作作为肺癌患者对酪氨酸激酶抑制剂治疗的反应
J Belg Soc Radiol. 2020 Jun 8;104(1):28. doi: 10.5334/jbsr.2163.
2
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.使用 RECIST 1.1 标准捕捉免疫检查点抑制剂的超进展性疾病。
Clin Cancer Res. 2020 Apr 15;26(8):1846-1855. doi: 10.1158/1078-0432.CCR-19-2226. Epub 2019 Nov 22.
3
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
4
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.早期免疫治疗试验中的超进展性疾病：临床预测因素及与免疫相关毒性的关联。
Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.
5
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer.免疫基因组格局促成癌症抗PD-1免疫治疗后的超进展性疾病。
iScience. 2018 Nov 30;9:258-277. doi: 10.1016/j.isci.2018.10.021. Epub 2018 Oct 25.
6
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
7
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
8
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
9
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
10
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
Zotero 插件